๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Xiamen
Clinical trial register · China

Clinical Trials in Xiamen, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
The First Affiliated Hospital of Xiamen University64 Merck Sharp & Dohme LLC36 Bristol-Myers Squibb11 BeOne Medicines10 AbbVie8
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Xiamen

382 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT07783100Relapsed or Refractory Acute Myeloid Leukemia
The First Affiliated Hospital of Xiamen University
Phase 2
30
Xiamen
2026-11-11
Not yet open
Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
NCT07821606Platinum-sensitive Recurrent Ovarian Cancer
Hansoh BioMedical R&D Company
Phase 3
460
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Shaoguan, Nanning, Harbin
2026-11-01
Not yet open
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic(PK/PD) Profile of ACT500 in Metabolic Dysfunction-Associated Steatotic Liver Disease(MASLD)
NCT07462455Metabolic Dysfunction-associated Steatohepatitis
Xiamen Amoytop Biotech Co., Ltd.
Phase 1
24
Beijing, Shanghai, Xi'an, Xiamen
2026-10-31
Not yet open
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of ACT500 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated With Chronic Hepatitis B
NCT07589400Metabolic Dysfunction-associated Steatotic Liver Disease, Chronic Hepatitis b
Xiamen Amoytop Biotech Co., Ltd.
Phase 1
24
Beijing, Shanghai, รœrรผmqi, Xiamen
2026-10-30
Recruiting
Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT07687459Idiopathic Pulmonary Fibrosis
InSilico Medicine Hong Kong Limited
Phase 3
320
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Nanning, Haikou, Shijiazhuang
2026-09-09
Not yet open
Real-World Study of the Safety and Efficacy of Surufatinib in the Treatment of Neuroendocrine Tumors
NCT07780539Neuroendocrine (NE) Tumors
Yefeng
Observational
60
Xiamen
2026-09-01
Not yet open
A Study of ATG-201 in Adult Participants With Autoimmune Diseases
NCT07732309Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Sjogren's Disease, Autoimmune Diseases
Antengene Biologics Limited
Phase 1
149
Bengbu, Hefei, Beijing, Xiamen, Guangzhou, Luoyang, Zhengzhou, Wuhan
2026-09-01
Not yet open
Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response
NCT07797231Chronic Hepatitis B
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
930
Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Wuwei
2026-09
Not yet open
Phase 3 Study to Evaluate the Efficacy and Safety of Human Growth Hormone Injection (Sinotropin AQ) for the Treatment of Children With Idiopathic Short Stature
NCT07815626Idiopathic Short Stature (ISS)
Zhongshan Sansure Hygene Biomedicine Co., Ltd.
Phase 3
240
Hefei, Beijing, Xiamen, Guangzhou, Tangshan, Wuhan, Changsha, Nanjing
2026-09
Recruiting
To Evaluate the Efficacy and Safety of Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) Combined With NBB-001 and NBB-002 for Patients With Recurrent Head and Neck Malignancies
NCT07795034Head and Neck Cancer
Neuboron Bio-SciTech Co., Ltd.
Phase 2
35
Xiamen
2026-08-31
Recruiting
Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL
NCT07778212DLBCL - Diffuse Large B Cell Lymphoma, Intermediate-High Risk, First-Line
The First Affiliated Hospital of Xiamen University
Not applicable
30
Xiamen
2026-08-30
Not yet open
Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis
NCT07683806Seborrheic Dermatitis
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 3
309
Bengbu, Wuhu, Fuzhou, Xiamen, Guangzhou, Shenzhen, Haikou, Baoding
2026-08-24
Not yet open
Zuberitamab in the First Episode of Paediatric Nephrotic Syndrome
NCT07765914Nephrotic Syndrome
Children's Hospital of Fudan University
Phase 3
120
Shanghai, Changsha, Guiyang, Wuhan, Wuxi, Xiamen
2026-08-20
Not yet open
Underdilated VCX-TIPS Versus EVL Plus NSBB for Secondary Prophylaxis of Variceal Bleeding in Cirrhosis
NCT07587671Liver Cirrhosis, Portal Hypertension, Gastroesophageal Varices Bleeding, Esophageal Varices
West China Hospital
Not applicable
240
Chengdu, Chongqing, Xiamen
2026-08-01
Not yet open
Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
NCT07064902Nasopharyngeal Carcinoma (NPC)
Sun Yat-sen University
Phase 2
48
Xiamen, Guangzhou, Guilin
2026-08-01
Not yet open
A Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung Cancer
NCT07771764ALK-positive Non Small Cell Lung Cancer
First Affiliated Hospital of Fujian Medical University
Phase 2
30
Fuzhou, Longyan, Quanzhou, Xiamen, Zhangzhou
2026-08-01
Not yet open
Inflammatory Markers and Prognosis After Cerebral Thrombectomy in Large Vessel Occlusion
NCT07754942Acute Ischemic Stroke, Large Vessel Occlusion
Zhongshan Hospital Xiamen University
Observational
50
Xiamen
2026-08-01
Recruiting
Trophoblast Cell-Surface Antigen 2 (Trop-2) Targeted PET/CT in Recurrent and Metastatic Thyroid Cancer
NCT07753499Tumor, Solid Tumor, Thyroid Cancer
The First Affiliated Hospital of Xiamen University
Not applicable
120
Xiamen
2026-08-01
Not yet open
Phase III Study of OT202 in Treating Moderate to Severe Dry Eye
NCT07740564Dry Eye
Ocumension Therapeutics (Suzhou) Co., Ltd
Phase 3
842
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou
2026-08
Not yet open
A Study to Evaluate the Efficacy and Safety of ICP-488 in Participants With Primary Sjรถgren's Syndrome
NCT07727486Primary Sjรถgren's Syndrome
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
240
Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Shijiazhuang, Changsha, Zhuzhou
2026-08
Not yet open
Clinical Study on the Effectiveness of Antibiotics Combined With Bifidobacterium Quadruple Live Tablets in Treating Cirrhosis With Spontaneous Bacterial Peritonitis and Preventing Recurrence
NCT07686861Cirrhosis With Spontaneous Bacterial Peritonitis
Peking University First Hospital
Phase 4
360
Fuyang, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shenzhen, Guigang, Guiyang
2026-07-31
Recruiting
A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours
NCT07533708mCRPC or Advanced/Metastatic Solid Tumors
Shanghai Henlius Biotech
Phase 1
48
Nanchang, Naning, Nanjing, Shanghai, Xiamen
2026-07-30
Recruiting
Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL
NCT07749365DLBCL - Diffuse Large B Cell Lymphoma, PCNSL (Primary CNS Lymphoma)
The First Affiliated Hospital of Xiamen University
Phase 2
53
Xiamen
2026-07-25
Not yet open
Development and Validation of a Colorectal Cancer Diagnostic Model
NCT07692555Colorectal Cancer, Advanced Neoplasia, Prediction Models, Risk Stratification
Peking University Cancer Hospital & Institute
Observational
20,000
Beijing, Fuzhou, Xiamen, Yinchuan
2026-07-15
Recruiting
A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT07622186Non-Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
150
Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Guangzhou, Guilin, Nanning
2026-07-15
Recruiting
A Study of MI078 for Postpartum Depression
NCT07721961Postpartum Depression (PPD)
Nanjing Minova Pharmaceutical Co., Ltd.
Phase 3
200
Hefei, Chongqing, Xiamen, Lanzhou, Guangzhou, Zhaoqing, Liuzhou, Guiyang
2026-07-10
Not yet open
Clinical Study of Traditional Chinese Medicine in the Treatment of Phlegm-dampness Intrinsic Precocious Puberty
NCT07637019Precocious Puberty
Children's Hospital of Fudan University
Not applicable
200
Xiamen, Guangzhou, Zhengzhou, Jinan, Shanghai
2026-07-01
Recruiting
Neoadjuvant RC48 Plus Gemcitabine in HER2-Expressing MIBC
NCT07693959MIBC
Zhiquan Hu
Phase 3
170
Hefei, Fuzhou, Xiamen, Guangzhou, Shenzhen, Enshi, Huanggang, Huangshi
2026-07-01
Not yet open
Chidamide Monotherapy for Intermediate-to-High-Risk Myelodysplastic Syndromes
NCT07616336Myelodysplastic Syndromes
Zhongshan Hospital (Xiamen), Fudan University
Phase 2
15
Xiamen
2026-07-01
Not yet open
Hexaminolevulinate Photodynamic Therapy (HAL-PDT) With Deferred Surgery Versus Surgery for High-grade Squamous Intraepithelial Lesions (HSIL)
NCT07669363Cervical Intraepithelial Neoplasia, Papillomavirus Infections
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
230
Fuzhou, Xiamen, Foshan, Guangzhou, Shenzhen, Zhongshan, Nanning, Dongguan
2026-07-01
Recruiting
Study of AHB-171 in Chronic Hepatitis B Participants
NCT07630727Hepatitis B, Chronic (CHB)
Ausper Biopharma Co., Ltd.
Phase 2
138
Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Zhengzhou, Changzhou, Jilin City
2026-06-24
Recruiting
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
NCT07554339Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
310
Hefei, Beijing, Xiamen, Nanning, Shijiazhuang, Wuhan, Changsha, Nanjing
2026-06-18
Recruiting
Safety, Pharmacokinetic (PK) Profile and Efficacy of Inpegsomatropin Injection in Adults With Growth Hormone Deficiency
NCT07551804Adult Growth Hormone Deficiency
Xiamen Amoytop Biotech Co., Ltd.
Phase 2
36
Beijing, Henan, Shanghai, Sichuan, Xiamen, Zhejiang
2026-06-10
Recruiting
ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management
NCT07517042Obesity, Weight Control
Shanghai Zhongshan Hospital
Not applicable
420
Chongqing, Fuzhou, Xiamen, Wuhan, Nanjing, Suzhou, Shanghai, Luzhou
2026-06-10
Recruiting
Percutaneous Pulmonary Artery Denervation (PADN) for the Treatment of Pulmonary Hypertension After Transcatheter Mitral Valve Edge-to-Edge Repair (M-TEER): A Prospective Cohort Study
NCT07662655Pulmonary Hypertension, Pulmonary Hypertension Associated With HFpEF
Xiamen Cardiovascular Hospital, Xiamen University
Phase EARLY_PHASE1
60
Xiamen
2026-06-06
Recruiting
A Study to Evaluate AHB-137 Injection in Treatment-naรฏve Participants With Chronic Hepatitis B
NCT07635186Chronic Hepatitis B
Ausper Biopharma Co., Ltd.
Phase 2
320
Beijing, Chongqing, Xiamen, Guangzhou, Jiangmen, Meizhou, Qingyuan, Shenzhen
2026-06-05
Recruiting
Tart Cherry Citrate Effervescent Tablet for Urate-Lowering Therapy in Participants With Asymptomatic Hyperuricemia
NCT07613138Hyperuricemia With or Without Gout
Beijing Zhecheng Biotechnology Co., Ltd.
Not applicable
196
Xiamen
2026-06-04
Recruiting
Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
NCT06993506HER2-negative Breast Cancer, Recurrence, Metastasis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
500
Hefei, Beijing, Fuzhou, Xiamen, Shijiazhuang, Zhengzhou, Shiyan, Wuhan
2026-05-28
Recruiting
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPROยฎ in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
NCT07477587Multiple Myeloma (MM)
Shanghai Henlius Biotech
Phase 1
258
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Meizhou
2026-05-27
Recruiting
A Study of SKB571 in Participants With Gastrointestinal Tumors
NCT07564466Gastrointestinal Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
120
Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Shijiazhuang, Harbin, Luoyang
2026-05-20
Recruiting
DLL3-Targeted PET/CT in Small Cell Lung Cancer
NCT07677787PET/CT, Small Cell Lung Cancer ( SCLC ), DLL3-targeted PET/CT, Delta-like Protein 3
The First Affiliated Hospital of Xiamen University
Not applicable
20
Xiamen
2026-05-09
Recruiting
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
NCT07415031Solid Tumors
Mirati Therapeutics Inc.
Phase 2
170
Beijing, Xiamen, Zhengzhou, Changsha, Nanjing, Nanchang, Shenyang, Jinan
2026-05-06
Recruiting
SAfety and eFfectiveness of cathetER Ablation for Atrial Fibrillation With Intracranial Hemorrhage (SAFER-AF)
NCT07316270AF - Atrial Fibrillation, Intracranial Hemorrhage, Spontaneous
Beijing Anzhen Hospital
Not applicable
646
Hefei, Beijing, Xiamen, Harbin, Changchun, Xi'an
2026-05-06
Recruiting
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
NCT07483099Crohn Disease
Eli Lilly and Company
Phase 2
60
Changsha, Changzhou, Guangzhou, Hangzhou, Huizhou, Suzhou, Wenzhou, Xiamen
2026-05-04
Recruiting
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
NCT07483073Colitis, Ulcerative, Crohn Disease
Eli Lilly and Company
Phase 2
60
Changsha, Changzhou, Guangzhou, Hangzhou, Huizhou, Suzhou, Wenzhou, Xiamen
2026-05-04
Recruiting
GPC3-Targeted PET/CT in Hepatocellular Carcinoma
NCT07677774Hepatocellular Carcinoma (HCC), Glypican-3, GPC3-targeted PET/CT
The First Affiliated Hospital of Xiamen University
Not applicable
40
Xiamen
2026-05-01
Not yet open
Multi-Site Cortical Puncture for DOR
NCT07568639Diminished Ovarian Reserve (DOR)
First Affiliated Hospital of Guangxi Medical University
Not applicable
214
Xiamen, Guigang, Liuzhou, Nanning, Qinzhou
2026-04-30
Recruiting
GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL
NCT06875063Non-hodgkin Lymphoma, Refractory Lymphoma, Chimeric Antigen Receptor T-cell
The First Affiliated Hospital of Xiamen University
Phase 1
45
Xiamen
2026-04-30
Recruiting
A Phase โ… b/โ…กa Clinical Study of IMC-003 Injection for the Treatment of Pulmonary Arterial Hypertension Receiving Background Therapy.
NCT07593027Pulmonary Arterial Hypertension PAH
ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
Phase 1/2
120
Beijing, Jilin City, Fuzhou, Xiamen, Lanzhou, Guangzhou, Guiyang, Zhengzhou
2026-04-30
Recruiting
Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease
NCT07547930Thyroid Eye Disease, TED, Graves Ophthalmopathy, Graves Orbitopathy
The First Affiliated Hospital of Xiamen University
Phase 2
8
Xiamen
2026-04-24
Recruiting
A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in China
NCT07588880Progressive Familial Intrahepatic Cholestasis
Ipsen
Observational
20
Beijing, Chongqing, Hunan, Nanjing, Shanghai, Xiamen
2026-04-16
Recruiting
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
NCT07385703Adenocarcinoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
752
Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Wuwei
2026-04-15
Recruiting
A Study of Zovaglutide (ZT002 Injection) in Participants With Impaired Kidney Function and Healthy Participants
NCT07443059Overweight , Obesity
Beijing QL Biopharmaceutical Co.,Ltd
Phase 1
40
Xiamen, Jinan, Chengdu
2026-04-13
Recruiting
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
NCT07416474Non-Small Cell Lung Cancer
RemeGen Co., Ltd.
Phase 3
574
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Dongguan, Guangzhou
2026-04-03
Not yet open
Decision Aid for Women Newly Diagnosed With Breast Cancer
NCT07497256Breast Cancer, Decision Aid, Shared Decision Making, Cost Effectiveness
Xiamen University
Not applicable
160
Xiamen
2026-04-01
Not yet open
Safety, Tolerability, and Preliminary Efficacy of Peginterferon ฮฑ-2b in Combination With an Anti-PD-1 Antibody in Patients With Advanced or Metastatic Malignant Solid Tumors
NCT07438093Advanced Solid Tumors
The First Affiliated Hospital of Xiamen University
Not applicable
60
Xiamen
2026-04
Not yet open
A Clinical Study to Evaluate the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects With Impaired Liver Function Versus Normal Liver Function
NCT07538973Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
24
Xiamen, Zhengzhou, Qingdao
2026-04
Recruiting
Human Umbilical Cord Mesenchymal Stem Cell-derived Small Extracellular Vesicles for the Treatment of Dry Eye Disease
NCT07623382Dry Eye Disease, Umbilical Cord Mesenchymal Stem Cell-derived Small Extracellular Vesicles
The First Affiliated Hospital of Xiamen University
Phase EARLY_PHASE1
20
Xiamen
2026-03-31
Recruiting
Remote Ischemic Preconditioning for Aute Type A Aortic Dissection Surgery
NCT07383909Aortic Dissection Type A
Fujian Medical University
Not applicable
1,312
Hefei, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Changsha, Dalian
2026-03-29
Recruiting
A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
NCT07405151Oesophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLC
Phase 1/2
60
Hefei, Beijing, Xiamen, Zhengzhou, Xuzhou, Jinan, Hangzhou
2026-03-27
Recruiting
To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus
NCT07447986Systemic Lupus Erythematosus (SLE)
Hangzhou Sumgen Biotech Co., Ltd.
Phase 2
120
Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Shenzhen, Guilin, Nanning
2026-03-26
Recruiting
A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy
NCT07487896Advanced Esophageal Squamous Cell Carcinoma
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3
440
Anqing, Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou
2026-03-24
Recruiting
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 โ‰ฅ 50%. (ROSETTA Lung-202)
NCT07361510Non-Small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb
Phase 3
750
Beijing, Fuzhou, Xiamen, Zhangzhou, Guangzhou, Shantou, Nanning, Harbin
2026-03-12
Recruiting
A Phase III Study of Deuremidevir Hydrobromide for the Treatment of RSV Infection in Infants and Young Children
NCT07402512Respiratory Syncytial Virus Infection
Simcere Pharmaceutical Co., Ltd
Phase 3
498
Xiamen, Changsha, Chengdu, Hangzhou
2026-03-11
Recruiting
Phase II Study of RC1416 Injection in COPD
NCT07402551Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Nanjing RegeneCore Biotech Co., Ltd.
Phase 2
180
Hefei, Suzhou, Chongqing, Xiamen, Guangzhou, Huizhou, Jiangmen, Qingyuan
2026-03-06
Recruiting
HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor
NCT07396584Solid Tumors, Adult
Hutchmed
Phase 1/2
186
Changchun, Changsha, Jinan, Nanning, Shanghai, Wuhan, Xiamen, Zhengzhou
2026-03-04
Recruiting
SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC
NCT07451795Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer)
Fudan University
Phase 2
66
Fujian, Shanghai, Xiamen
2026-03-02
Not yet open
A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren Syndrome
NCT07375524Primary Sjรถgren Syndrome
Shanghai Escugen Biotechnology Co., Ltd
Phase 2
40
Beijing, Xiamen, Guilin, Langfang, Changde, Changsha, Zhuzhou, Xuzhou
2026-03-01
Not yet open
A Study to Evaluate the Safety and Effectiveness of Perfluorohexyloctane Eye Drops on Treatment of Dry Eye Disease (DED) Related to Meibomian Gland Dysfunction (MGD)
NCT07457021Dry Eye Disease
Xiamen Ophthalmology Center Affiliated to Xiamen University
Observational
2,000
Xiamen
2026-03-01
Not yet open
A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs
NCT07483684HER2 IHC3+ Advanced Colorectal Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
142
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Meizhou
2026-03
Recruiting
A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07327229Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Antengene Biologics Limited
Phase 1/2
132
Hefei, Beijing, Fuzhou, Xiamen, Lanzhou, Langfang, Shijiazhuang, Anyang
2026-02-27
Recruiting
Adult and Adolescent Hemophilia Patients Treated With Marstacimab: a Patient Experience Registry
NCT06992076Hemophilia
Institute of Hematology & Blood Diseases Hospital, China
Observational
100
Xiamen, Tianjin
2026-02-15
Recruiting
Factors for Prolonged Hospital Stays in Patients Undergoing ERCP
NCT07568626Post-ERCP Adverse Events, ERCP Complications
Air Force Military Medical University, China
Observational
504
Xiamen, Xi'an
2026-02-15
Not yet open
Evaluation of the Pharmacokinetics of Curcumin Capsules in Healthy Human
NCT07379177Healthy
Kingdomway (Inner Mongolia) Nutritional Food Co., Ltd.
Not applicable
12
Xiamen
2026-01-28
Recruiting
A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
NCT07347600Locally Advanced Breast Cancer, Metastatic Breast Cancer
Hoffmann-La Roche
Observational
500
Xiamen, Lanzhou, Changchun, Wenzhou, Beijing, Chengdu, Chongqing, Guangzhou
2026-01-21
Recruiting
Bacillus Subtilis and Enterococcus Faecium Probiotic Plus Lipid-Lowering Therapy for Hypertriglyceridemic Acute Pancreatitis: A Prospective RCT
NCT07720232Hypertriglyceridemic Acute Pancreatitis, Acute Pancreatitis, Hypertriglyceridemia-induced, Hyperlipidemia
Jianyin Zhou
Phase 4
180
Xiamen
2026-01-18
Recruiting
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
NCT07063745Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Bristol-Myers Squibb
Phase 2/3
590
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Nanning
2026-01-02
Active, closed
DIEP-MDS for Risk Stratification of Flap Vascular Compromise and Failure in Breast Reconstruction
NCT07761390Breast Neoplasms, Breast Reconstruction, Postoperative Complications
Zhuliling
Observational
1,500
Xiamen, Dongguan, Guangzhou, Huizhou, Meizhou, Shantou, Shanwei, Shaoguan
2026-01-01
Not yet open
Left Ventricular Myocardial Work for Predicting Response to CRT
NCT07319065CRT Non-Response, LBBB, HF - Heart Failure, Healthy Adult
First Hospital of China Medical University
Observational
3,240
Hefei, Wannan, Fuzhou, Guizhou, Xiamen, Lanzhou, Jiangmen, Qinhuangdao
2026-01-01
Recruiting
A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
NCT07143045EGFR Mutant Advanced Non-small Cell Lung Cancer, Central Nervous System (CNS) Metastases
Alpha Biopharma (Jiangsu) Co., Ltd.
Observational
800
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Foshan, Guangzhou, Meizhou
2025-12-29
Recruiting
A Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSL
NCT07350850PCNSL, Primary Central Nervous System Lymphoma
Tongji Hospital
Phase 2
77
Xiamen, Wuhan, Changchun, Taiyuan
2025-12-25
Recruiting
Safety and Pharmacokinetics of NM6603 in Chinese Patients With Advanced Solid Tumors
NCT07292038Cancers
NucMito Pharmaceuticals Co. Ltd.
Phase 1
30
Xiamen, Guangzhou, Zhengzhou
2025-12-18
Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing
ArriVent BioPharma, Inc.
Phase 3
480
Beijing, Xiamen, Foshan, Shantou, Shijiazhuang, Harbin, Luoyang, Xinxiang
2025-12-17
Recruiting
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
NCT07222267Breast Cancer, Advanced Solid Tumor
BeOne Medicines
Phase 1
86
Beijing, Chongqing, Xiamen, Guangzhou, Harbin, Nanjing, Shanghai, Tianjin
2025-12-11
Recruiting
Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT06992739NSCLC (Advanced Non-small Cell Lung Cancer), EGFR, Myelosuppression
The First Affiliated Hospital of Xiamen University
Phase 2
49
Xiamen
2025-12-08
Recruiting
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
NCT07209111Neoplasm Malignant
Merck Sharp & Dohme LLC
Phase 2
150
Beijing, Xiamen, Guangzhou, Harbin, Wuhan, Changsha, Nanjing, Nanchang
2025-12-04
Recruiting
Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
NCT07165951Metastatic Pancreatic Ductal Adenocarcinoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
566
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shenzhen
2025-12-02
Recruiting
DLL3-Targeted PET/CT in Neuroendocrine Carcinoma
NCT07458906DLL3-expressing Tumors, PET / CT, Neuroendocrine Cancer
The First Affiliated Hospital of Xiamen University
Not applicable
60
Xiamen
2025-12-01
Recruiting
A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
NCT07282353Primary Biliary Cholangitis
Cascade Pharmaceuticals, Inc
Phase 3
135
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Shenzhen, Zhanjiang, Nanning
2025-12-01
Not yet open
Prospective Cohort Study of Neuromyelitis Optica Spectrum Disorders (NMOSD)
NCT07266051NMOSD
Xiamen Hospital of Traditional Chinese Medicine
Observational
4,000
Xiamen
2025-12
Recruiting
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
NCT07218146Small-cell Lung Cancer
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
Hefei, Fuzhou, Xiamen, Guangzhou, Naning, Heilongjiang, Shijiazhuang, Zhengzhou
2025-11-30
Recruiting
A Phase โ… /โ…กa Clinical Study of GEN-725 in Combination With Dositinib
NCT07362940Non-Small Cell Lung Cancer
Henan Genuine Biotech Co., Ltd.
Phase 1/2
110
Beijing, Changsha, Jinan, Xiamen, Zhengzhou
2025-11-27
Recruiting
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
NCT07286175Bipolar Disorder
Eli Lilly and Company
Phase 2
400
Changsha, Hangzhou, Huzhou, Jinan, Shanghai, Shijiazhuang, Tianjin, Xiamen
2025-11-24
Recruiting
Neuroendoscopy-assisted Drainage Versus Burr Hole Drainage for Chronic Subdural Hematoma
NCT07144423Chronic Subdural Hematoma
Beijing Tiantan Hospital
Not applicable
770
Beijing, Xiamen, Jiangmen, Shantou, Shenzhen, Liuzhou, Nanning, Wuzhou
2025-11-19
Recruiting
Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma
NCT07182565Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy
West China Hospital
Phase 1/2
84
Xiamen, Chengdu
2025-11-18
Recruiting
BDB-001 Phase III Trial in ANCA-Associated Vasculitis
NCT07168161ANCA Associated Vasculitis (AAV)
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Phase 3
300
Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Meizhou, Shaoguan, Shenzhen
2025-11-10
Recruiting
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
NCT07181681Solid Tumors, Advanced Solid Tumor
BeOne Medicines
Phase 1
63
Beijing, Chongqing, Xiamen, Zhengzhou, Shanghai, Chengdu, Hangzhou
2025-11-10
Recruiting
Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease
NCT07228364Autosomal Dominant Polycystic Kidney Disease
AstraZeneca
Phase 1
40
Chengdu, Hangzhou, Nanjing, Shanghai, Wuhan, Xiamen
2025-11-10
Recruiting
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
NCT07258979Recurrent or Metastatic Nasopharyngeal Carcinoma
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
202
Chongqing, Fuzhou, Xiamen, Zhangzhou, Dongguan, Guangzhou, Jiangmen, Shaoguan
2025-11-05
Recruiting
the Effect of Transcutaneous Electrical Acupoint Stimulation on Postoperative Gastrointestinal Dysfunction After Urological Laparoscopic Surgery
NCT07133620Postoperative Gastrointestinal Dysfunction (POGD)
The First Affiliated Hospital of Xiamen University
Not applicable
112
Xiamen
2025-11-01
Rows per page Showing 1–100 of 382
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/xiamen

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 382 of those studies with a site in Xiamen.

How many clinical trials are recruiting in Xiamen?

243 of the 382 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 45 have not yet opened recruitment, 91 are active but closed to new participants, and 3 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Xiamen), 382 studies
PhaseStudiesRecruitingShare
Phase 31316034.3%
Phase 2685417.8%
Observational493012.8%
Not applicable473512.3%
Phase 1/2392910.2%
Phase 125186.5%
Phase 2/31082.6%
Phase 41072.6%
Phase EARLY_PHASE1320.8%

Most active sponsors

Lead sponsors with the most studies (Xiamen)
Lead sponsorStudiesRecruiting
The First Affiliated Hospital of Xiamen University6455
Merck Sharp & Dohme LLC3619
Bristol-Myers Squibb116
BeOne Medicines107
AbbVie82
RemeGen Co., Ltd.76
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.62
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.65
Ausper Biopharma Co., Ltd.54
Eli Lilly and Company53
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.